Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis

Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis

<i>Background and Objectives</i>: Treatment for elderly (aged ≥75 years) patients with rheumatoid arthritis (RA) is important because they usually have several complications and organ dysfunction and are more susceptible to drug-related adverse events. Abatacept (ABT) treatment is relati...

Full description

Bibliographic Details
Main Authors: Shuzo Sato, Haruki Matsumoto, Jumpei Temmoku, Yuya Fujita, Naoki Matsuoka, Makiko Yashiro-Furuya, Tomoyuki Asano, Eiji Suzuki, Hiroshi Watanabe, Takashi Kanno, Kiyoshi Migita
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Medicina
Subjects:
abatacept
DMARD
elderly
rheumatoid arthritis
tacrolimus
Online Access:https://www.mdpi.com/1648-9144/57/9/914

Internet

https://www.mdpi.com/1648-9144/57/9/914

Similar Items